Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Stock Information for Lipocine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lipocine Inc.

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO(TM)) as a Treatment for Postpartum Depression on July 9, 2025
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.